Guggenheim reiterates Merck stock rating ahead of earnings By Investing.com

Guggenheim reiterated a Buy and $140 price target on MRK while trimming FY2026 sales to $66.29B from $66.97B and lowering FY2026 EPS to $5.06 from $5.12; Q1'26 sales were cut to $16.0B (from $16.15B) while Q1 EPS was nudged to $1.47 from $1.45. Jefferies raised its PT to $138 (from $132) with a Buy, while Cantor Fitzgerald kept a Neutral $120 target; Merck market cap is ~$304.55B with LTM revenue of $65.01B. Positive pipeline news includes the start of a pivotal Phase 2b/3 trial for MK-8748 and strong Phase 3 cholesterol results for enlicitide, but analysts remain mixed on CADENCE sotatercept data and Keytruda revenue pressure remains a near-term focus.

Analysis

The market is repricing a large-cap pharmaceutical name around near-term revenue trajectory and the contribution of recently acquired assets. Expect the next earnings call and upcoming mid-stage/late-stage readouts to drive distinct volatility regimes: narrow, technical moves around the print (days-to-weeks) and larger fundamental re-ratings if clinical/regulatory outcomes diverge from investor expectations (months).

Competitive dynamics favor players that can both execute rapid commercial rollouts and scale biologics manufacturing without material margin dilution; smaller biotech sellers of niche assets gain optionality via sales milestones and royalty streams, while large CMOs could see demand spikes if multiple acquirers accelerate launches. Payer/reimbursement shifts are the underappreciated torque—changes to coding or coverage can flip uptake curves within one quarter and amplify or mute the benefit of new launches.

Key tail risks include dose-response or safety surprises in pivotal programs, integration friction for recently acquired assets, and adverse reimbursement rulings; any of these can compress free cash flow conversion over 12–24 months and justify multiple contraction. Conversely, successful readouts and smooth payer access could meaningfully narrow perceived replacement risk for the legacy franchise and support upside in the 6–18 month window.

Monitor three high-signal metrics in real time: sequential sales momentum for newly launched products (weekly scripts/claims data), COGS trends in quarterly filings, and early reimbursement uptake indicators (billing code adoption rates). These will separate transient noise from durable trajectory changes.

Key Decisions for Investors

• Directional equity with defined downside: Buy MRK stock for a 6–12 month hold (size 3–5% of equity allocation) and buy a 10% OTM put with 9–12 month tenor as tail protection; reward if key readouts and reimbursement uptake beat expectations while limiting downside to ~10% at cost of the put premium.
• Event-driven limited-risk upside: Enter a 3–6 month call spread (buy 1x near-the-money call, sell 1x +15–25% OTM call) ahead of the next earnings and major trial readouts to capture asymmetric upside while capping premium outlay; target 2.5x–4x return if catalysts print positive, max loss = premium.
• Relative-value pair: Long MRK / Short BMY (equal notional) for 6–12 months to express conviction in better pipeline diversification and integration optionality; set stop if pair underperforms by 8% relative to entry, target 6–10% absolute relative outperformance.
• Hedged upside on binary readout: If unwilling to hold through headline risk, sell short-dated (30–45 day) put spreads to collect premium into the earnings window (max loss defined by spread width) and simultaneously buy a further-dated call to retain upside exposure if results surprise positively.
• Liquidity and monitoring rule: Reduce position by 30–50% within 48 hours if claims data and gross margin guidance both miss sequential trends; conversely, add 25–50% on clear sequential acceleration across sales and reimbursement adoption indicators within one quarter.